Abstract: The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.

Abstract: An approach is provided for optimizing a just-in-time (JIT) compilation process. A source pod in a container orchestrated execution environment is determined to be saturated. Profile data from a JIT compiler, a virtual machine state, and a native-compiled code state are collected. The profile data, virtual machine state, and native-compiled code state are stored in a data structure in a persistent data repository. In response to a restart or a redeployment of the source pod and an application running on the source pod, the stored profile data, virtual machine state, and native-compiled code state are reused in a new target pod, without requiring a monitoring and an identification of hot code areas in the application after the source pod becomes saturated.

Abstract: An approach is provided for optimizing a just-in-time (JIT) compilation process. A source pod in a container orchestrated execution environment is determined to be saturated. Profile data from a JIT compiler, a virtual machine state, and a native-compiled code state are collected. The profile data, virtual machine state, and native-compiled code state are stored in a data structure in a persistent data repository. In response to a restart or a redeployment of the source pod and an application running on the source pod, the stored profile data, virtual machine state, and native-compiled code state are reused in a new target pod, without requiring a monitoring and an identification of hot code areas in the application after the source pod becomes saturated.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: Execution of varying tasks for heterogeneous applications running in a single runtime environment is managed. The runtime environment is capable of managing thread pools for any of the plurality of applications and receives a request to manage a thread pool for one of the applications. The request includes size thresholds for the pool, a first function to be invoked for creation of threads, and a second function to be invoked for termination of the threads. Responsive to detecting that a first size threshold is not satisfied, the runtime environment invokes the first function to cause the application to create an additional thread. Responsive to detecting that a second size threshold is not satisfied, the runtime environment places an artificial task that incorporates the second function into a work queue for the thread pool, whereby a thread executes the artificial task to invoke the second function and thereby terminates.

Abstract: Execution of varying tasks for heterogeneous applications running in a single runtime environment is managed. The runtime environment is capable of managing thread pools for any of the plurality of applications and receives a request to manage a thread pool for one of the applications. The request includes size thresholds for the pool, a first function to be invoked for creation of threads, and a second function to be invoked for termination of the threads. Responsive to detecting that a first size threshold is not satisfied, the runtime environment invokes the first function to cause the application to create an additional thread. Responsive to detecting that a second size threshold is not satisfied, the runtime environment places an artificial task that incorporates the second function into a work queue for the thread pool, whereby a thread executes the artificial task to invoke the second function and thereby terminates.

Abstract: A method, computer program product, and visual display apparatus include a processor(s) obtaining data indicating that a user wearing the apparatus (which included an image capture device, and a projection device, communicatively coupled to the processor(s)), perceives displayed text with consistent character differences. The processor(s) obtains, from the image capture device, an image of a visual display within a visual range of the image capture device; the image includes textual elements. Based on the data, the processor(s) transforms the image into the new image that includes the textual elements with pre-defined character substitutions, based on the consistent character differences. The processor(s) displays, via the projection device, the new image, to the user, wherein based on viewing the new image, the user views the textual elements without the consistent character differences.

Abstract: A method, computer program product, and visual display apparatus include a processor(s) obtaining data indicating that a user wearing the apparatus (which included an image capture device, and a projection device, communicatively coupled to the processor(s)), perceives displayed text with consistent character differences. The processor(s) obtains, from the image capture device, an image of a visual display within a visual range of the image capture device; the image includes textual elements. Based on the data, the processor(s) transforms the image into the new image that includes the textual elements with pre-defined character substitutions, based on the consistent character differences. The processor(s) displays, via the projection device, the new image, to the user, wherein based on viewing the new image, the user views the textual elements without the consistent character differences.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: Methods, computer program products, and systems are presented. The method computer program products, and systems can include, for instance: obtaining from a plurality of computing environments computing environment characterizing data; obtaining application parameter data defined by an application provider, the application parameter data specifying attributes of an application component group defining an application, wherein the application parameter data includes group membership specifying data that specifies that certain application components are to be deployed as a group in a common computing environment; determining, in dependence on data of the computing environment characterizing data and data of the application parameter data, a set of computing environments for deployment of the application component group, and a placement ratio for the application component group.

Abstract: Methods, computer program products, and systems are presented.

Abstract: Character input error correction is provided by receiving from a keyboard character input by a user. The character input includes character input errors by the user, the character input errors being input of incorrect characters by the user via the keyboard. The character input errors of the character input are automatically identified and classified into character error classification(s). Each character error classification corresponds to a respective visual transformation of input characters. It is determined that a frequency of the identified and classified character input errors exceeds a predefined threshold confidence level for triggering application of keyboard corrections for user input. Based on the determining, keyboard corrections are applied for user input. The applying keyboard corrections includes applying a correction to character(s) displayed for or input by the user. The applied correction is based on at least one of the classification(s) into which the character input errors are classified.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

Abstract: A method, computer program product, and visual display apparatus include a processor(s) obtaining data indicating that a user wearing the apparatus (which included an image capture device, and a projection device, communicatively coupled to the processor(s)), perceives displayed text with consistent character differences. The processor(s) obtains, from the image capture device, an image of a visual display within a visual range of the image capture device; the image includes textual elements. Based on the data, the processor(s) transforms the image into the new image that includes the textual elements with pre-defined character substitutions, based on the consistent character differences. The processor(s) displays, via the projection device, the new image, to the user, wherein based on viewing the new image, the user views the textual elements without the consistent character differences.

Abstract: Character input error correction is provided by receiving from a keyboard character input by a user. The character input includes character input errors by the user, the character input errors being input of incorrect characters by the user via the keyboard. The character input errors of the character input are automatically identified and classified into character error classification(s). Each character error classification corresponds to a respective visual transformation of input characters. It is determined that a frequency of the identified and classified character input errors exceeds a predefined threshold confidence level for triggering application of keyboard corrections for user input. Based on the determining, keyboard corrections are applied for user input. The applying keyboard corrections includes applying a correction to character(s) displayed for or input by the user. The applied correction is based on at least one of the classification(s) into which the character input errors are classified.

Abstract: Character input error correction is provided by receiving from a keyboard character input by a user. The character input includes character input errors by the user, the character input errors being input of incorrect characters by the user via the keyboard. The character input errors of the character input are automatically identified and classified into character error classification(s). Each character error classification corresponds to a respective visual transformation of input characters. It is determined that a frequency of the identified and classified character input errors exceeds a predefined threshold confidence level for triggering application of keyboard corrections for user input. Based on the determining, keyboard corrections are applied for user input. The applying keyboard corrections includes applying a correction to character(s) displayed for or input by the user. The applied correction is based on at least one of the classification(s) into which the character input errors are classified.

Abstract: A method, computer program product, and visual display apparatus include a processor(s) obtaining data indicating that a user wearing the apparatus (which included an image capture device, and a projection device, communicatively coupled to the processor(s)), perceives displayed text with consistent character differences. The processor(s) obtains, from the image capture device, an image of a visual display within a visual range of the image capture device; the image includes textual elements. Based on the data, the processor(s) transforms the image into the new image that includes the textual elements with pre-defined character substitutions, based on the consistent character differences. The processor(s) displays, via the projection device, the new image, to the user, wherein based on viewing the new image, the user views the textual elements without the consistent character differences.

Abstract: Character input error correction is provided by receiving from a keyboard character input by a user. The character input includes character input errors by the user, the character input errors being input of incorrect characters by the user via the keyboard. The character input errors of the character input are automatically identified and classified into character error classification(s). Each character error classification corresponds to a respective visual transformation of input characters. It is determined that a frequency of the identified and classified character input errors exceeds a predefined threshold confidence level for triggering application of keyboard corrections for user input. Based on the determining, keyboard corrections are applied for user input. The applying keyboard corrections includes applying a correction to character(s) displayed for or input by the user. The applied correction is based on at least one of the classification(s) into which the character input errors are classified.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor and a decreased binding capacity for IL-2R?c receptor, as compared to wild-type IL-2. Such IL-2 muteins are useful, for example, as IL-2 partial agonist and antagonists in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of graft versus host disease (GVHD) and adult T cell leukemia). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.